On Monday, Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81.
This proprietary rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major indexes.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of above 80 as they launch their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
While now is not an ideal time to jump in, see if the stock is able to offer and clear a proper buy point.
While sales growth fell last quarter from 14% to 6%, EPS grew 1,250%, up from 0% in the prior report.
Supernus Pharmaceuticals holds the No. 21 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
